The core challenge in clinical oncology is time. Catching a tumor at its earliest stages drastically improves patient survival, yet conventional diagnostic tools are structurally ill-equipped for early screening. Procedures like tissue biopsies and endoscopies are highly invasive, expensive, and suffer from low patient compliance, meaning malignancies are frequently uncovered only after reaching advanced, symptomatic stages.
To bridge this gap, a major paradigm shift is underway toward noninvasive molecular biomarkers. By sampling stable, easily accessible indicators found in peripheral biofluids—such as blood, stool, or urine—clinicians can detect early oncogenic shifts and predict patient outcomes without relying on invasive interventions.
The Stability of Circulating Non-Coding RNAs
Why do non-coding RNAs serve as effective early warning systems? Unlike messenger RNAs, which are rapidly degraded by extracellular enzymes, non-coding RNAs—including long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and PIWI-interacting RNAs (piRNAs)—are frequently packaged into protective extracellular vesicles or bound to protein complexes. This structural resilience allows them to persist intact within harsh biofluid environments.
As a tumor develops, its altered transcriptional landscape sheds these stable RNA molecules into circulation. Ting Shi et al. highlight that lncRNAs can be reliably isolated from body fluids, offering a highly sensitive window into early oncogenesis and patient prognosis in Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics.
This principle applies directly to localized screening. For instance, in microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer, Tung On Yau et al. demonstrated that elevated levels of microRNA-20a (miR-20a) in stool samples can effectively distinguish colorectal cancer patients from healthy individuals, bypassing the need for immediate colonoscopy.
Furthermore, the diagnostic repertoire extends to even smaller RNA species. In PIWI-Interacting RNAs (piRNAs): Promising Applications as Emerging Biomarkers for Digestive System Cancer, Aiting Cai et al. show that piRNAs act as highly stable epigenetic regulators whose expression shifts predictably in digestive system cancers, providing clear diagnostic signals before macroscopic structural changes occur.
Metabolic and Microbial Footprints in Biofluids
The utility of noninvasive screening extends beyond nucleic acids to the metabolic and microbial shifts triggered by developing tumors. Because cancer cells fundamentally reprogram cellular metabolism, they release distinct chemical byproducts into the bloodstream long before physical symptoms manifest.
Using advanced analytical techniques like liquid chromatography-tandem mass spectrometry, the authors of Screening of serum oxysterol biomarkers for colon cancer by liquid chromatography-tandem mass spectrometry, led by Zhanjun Ma et al., identified specific serum oxysterols—such as 4β-hydroxycholesterol—that serve as highly accurate metabolic markers for early colon cancer.
Concurrently, systemic peptide levels can mirror early-stage pathology. In Circulating ghrelin levels in patients with gastric cancer: a systematic review and meta-analysis, Yuxuan Wang et al. established that circulating ghrelin levels drop significantly in gastric cancer patients, offering a potential blood-based screening tool for an otherwise asymptomatic early phase.
Even the local microbiome responds to and drives oncogenesis. Yujia Ke et al. note in Global status and trends of gastric cancer and gastric microbiota research: a bibliometric analysis a clear shift toward microbial dysbiosis indices, such as the enrichment of Fusobacterium nucleatum, which can be tracked noninvasively to flag early gastric malignancies.
This concept of leveraging accessible biofluid markers to monitor internal organ states is also mirrored in related fields; Mingjun Si et al. demonstrated in Triglycerides as Biomarker for Predicting Systemic Lupus Erythematosus Related Kidney Injury of Negative Proteinuria that serum triglycerides can noninvasively predict kidney injury when traditional markers like proteinuria are absent.
Mapping Biomarkers to Oncogenic Pathways for Prognosis
Why do these biomarkers correlate so tightly with clinical outcomes? They are not merely passive cellular debris; they are active components of the signaling pathways driving tumor progression, metastasis, and immune evasion. By quantifying these molecules, clinicians can infer the underlying aggressiveness of the disease.
Gastric and Colorectal Cancer Pathways
In Long noncoding RNA DLGAP1-AS2 facilitates Wnt1 transcription through physically interacting with Six3 and drives the malignancy of gastric cancer, Ji Mao demonstrated that the lncRNA DLGAP1-AS2 acts as a molecular decoy that prevents the silencing of the Wnt1 gene, driving gastric cancer malignancy.
In colorectal cancer, Jinsuo Gao et al. showed in Prognostic Analysis of LncRNA MCM3AP‐AS1 in Colorectal Cancer and the Mechanism of Its Effect on Tumor Cell Activity that the lncRNA MCM3AP-AS1 promotes proliferation and invasion by activating the VEGF/VEGFR2 pathway.
Similarly, Shuping Lou et al. found in PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT signaling pathway that the imprinted gene PHLDA2 regulates epithelial-mesenchymal transition (EMT) and autophagy via PI3K/AKT signaling.
Furthermore, Tao Li et al. identified CHI3L1 as a driver of the CD44-β-catenin pathway in CHI3L1: a key driver in gastritis-to-cancer transformation, marking the critical transition from chronic inflammation to malignant gastric cancer.
Renal and Lung Cancer Indicators
In clear cell renal cell carcinoma (ccRCC), microRNAs like miR-4429 act as tumor suppressors by directly targeting the immune checkpoint protein CD274 (PD-L1), as shown by Guangyi Hong et al. in miR-4429 inhibits ccRCC proliferation, migration, and invasion by directly targeting CD274.
Conversely, Fang Nie et al. uncovered a complex balancing act in MicroRNA-148b enhances proliferation and apoptosis in human renal cancer cells via directly targeting MAP3K9, where miR-148b targets the MAP3K9/JNK pathway to alter proliferation and apoptosis.
These molecular states directly shape the tumor microenvironment. Feng Li et al. identified UBE2I nuclear accumulation as a key diagnostic indicator in Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry, while Ke Xu et al. demonstrated in SLC22A8: An indicator for tumor immune microenvironment and prognosis of ccRCC from a comprehensive analysis of bioinformatics that low expression of SLC22A8 signals a highly immune-infiltrated microenvironment and poor prognosis.
Similar prognostic mapping applies across other aggressive malignancies. Shiqiang Dong et al. conducted a pan-cancer analysis in Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of MITD1, revealing the prognostic value of MITD1 in predicting immunotherapy responses.
In lung cancer, Manman Liang et al. showed in E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway that the E3 ligase TRIM15 drives progression by mediating the Keap1-Nrf2 antioxidant pathway, while Wei Cheng et al. linked Nanog overexpression to poor differentiation and metastasis in The Prognostic Value of Nanog Overexpression in Lung Cancer: A Meta-Analysis.
Finally, Xiaojin Wu et al. demonstrated in High Mobility Group Box Protein 1 Serves as a Potential Prognostic Marker of Lung Cancer and Promotes Its Invasion and Metastasis by Matrix Metalloproteinase-2 in a Nuclear Factor-κB-Dependent Manner that HMGB1 promotes lung cancer invasion by upregulating MMP-2 via the NF-κB pathway, cementing its utility as a reliable prognostic marker.
Key Foundational Work
microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer (2015) — contributed 1 concept elements to this direction.
Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics (2016) — contributed 1 concept elements to this direction.
Prediction of colorectal cancer diagnosis based on circulating plasma proteins (2015) — contributed 1 concept elements to this direction.